Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Danazol
Drug ID BADD_D00576
Description A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Indications and Usage For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
Marketing Status approved
ATC Code G03XA01
DrugBank ID DB01406
KEGG ID D00289
MeSH ID D003613
PubChem ID 28417
TTD Drug ID D09IPV
NDC Product Code 38779-0174; 0555-0635; 0555-0633; 62135-477; 0527-1369; 71205-862; 0527-1392; 53104-7501; 71052-662; 62135-476; 62135-475; 0527-1368; 49452-2436; 71205-861; 49076-5201; 0555-0634
UNII N29QWW3BUO
Synonyms Danazol | Danazant | Panacrine | Danocrine | Ladogal | Cyclomen | Danatrol | Danol | Danoval | Norciden | Azol | Danazol-Ratiopharm | Danazol Ratiopharm
Chemical Information
Molecular Formula C22H27NO2
CAS Registry Number 17230-88-5
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hirsutism23.02.04.001; 05.05.01.005--
Hyperhidrosis23.02.03.004; 08.01.03.0280.002361%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.002361%
Hypertrophy08.03.04.005--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Injection site haemorrhage08.02.03.005; 24.07.01.010; 12.07.03.0050.002361%Not Available
Insomnia19.02.01.002; 17.15.03.0020.002361%
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.003541%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint swelling15.01.02.004--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Lipids abnormal13.12.02.001--Not Available
Liver disorder09.01.08.0010.002361%Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.0030.004722%
Memory impairment19.20.01.003; 17.03.02.003--
Menstrual disorder21.01.01.004--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood swings19.04.03.001--Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene